Most laboratories have a test catalog. Fewer have a controlled definition of a laboratory service.
Those are not the same thing.
A catalog is often treated as a menu: test names, local codes, specimen types, prices, and ordering notes. That approach breaks down in clinical genomics and molecular diagnostics. A hereditary cancer panel, pharmacogenomics assay, carrier screen, exome, or rare-disease test is not simply an item a clinician selects. It is a set of connected commitments about what the laboratory will accept, perform, interpret, report, and deliver.
The operating question is not whether every detail sits in one application. It is whether the laboratory can show, for any accessioned case, that the service ordered, the service performed, and the report issued were governed by one coherent and approved definition.
That is the real purpose of genetic test catalog management.
Genetic Test Catalog Management Is More Than a Laboratory Test Menu
A laboratory test menu answers a basic question: What tests do we offer?
A clinical control system answers harder ones:
- What exactly did the clinician order?
- Which version of the genetic test was applied to this patient and case?
- Was the specimen acceptable for that assay version?
- Which genetic test consent, provider attestation, or supporting documentation rule applied?
- Which local test code, LOINC mapping, and interface rule identified the service?
- Which analysis configuration was authorized?
- Which report template, methodology, and limitations were applied?
- Can the laboratory reconstruct those decisions after the report is delivered?
The difference matters because a laboratory does not deliver a test name. It delivers a clinical service under defined conditions.
The Clinical Laboratory Improvement Amendments, or CLIA, require laboratories performing nonwaived testing to establish and maintain written policies and procedures for quality systems across preanalytic, analytic, postanalytic, and general laboratory activities. CMS guidance also states that laboratories need adequate manual or electronic systems to ensure results and patient-specific data are accurately and reliably sent from data entry to the final report destination. CMS CLIA interpretive guidance describes these expectations for laboratory quality systems, result transmission, and reporting.
A spreadsheet can document a test name. It does not, by itself, control the relationships that determine whether the laboratory can reliably receive, perform, report, and deliver that service.
Connect the rules that govern complex diagnostic workflows.
NonStop engineers connected clinical genomics systems that link test definition, intake, laboratory operations, analysis, reporting, integration, and downstream action.
A Genetic Test Catalog Connects Seven Clinical and Operational Commitments
No single team owns every condition attached to a clinical test. Genetic test catalog management therefore needs cross-functional ownership and controlled relationships among the records that define the service.
| Commitment | What the catalog must define | Failure when disconnected |
|---|---|---|
| Clinical | Intended use, indication, eligibility, ordering guidance, exclusions | The wrong test is ordered or the laboratory accepts a case outside approved policy |
| Consent | Required consent, attestation, disclosure, documentation, review triggers, exception path | Intake accepts incomplete or mismatched documentation, or staff rely on manual memory |
| Analytical | Assay version, gene content, variant classes, reportable range, methodology, limitations | The laboratory cannot establish which analytical service applied to a case |
| Operational | Specimen type, collection instructions, transport, rejection rules, turnaround, reflex rules | Preventable preanalytic exceptions enter downstream workflow |
| Informatic | Local code, provider-facing name, LOINC, EHR mapping, accessioning identifiers, interface behavior | External orders map incorrectly or duplicate services become indistinguishable |
| Reporting | Report template, result categories, methodology, limitations, structured fields, sign-out eligibility | Report language does not match the assay performed |
| Commercial | CPT, diagnosis-code dependencies, payer workflows, authorization and financial-policy rules | Billing and authorization work becomes detached from the clinical service definition |
Genetic testing adds dependencies that ordinary catalog models often miss: genes and transcripts, reportable ranges, family-history requirements, secondary-finding policies, reanalysis rules, and sensitive information with implications for relatives.
CDC guidance for molecular genetic testing notes that laboratories need enough patient and test-request information to perform testing and report results accurately. It also distinguishes CLIA from broader consent responsibilities: CLIA itself does not require laboratories to document informed consent for requested tests, while state or local requirements, institutional policies, provider responsibilities, and test-specific considerations may apply. CDC guidance for molecular genetic testing provides that context.
A catalog should not merely store a link to a consent form. It should support an operational determination: Does the documentation satisfy the approved rule for this patient, this test, and this service version?
The outcome may be an automated pass, a hold, an exception queue, or qualified human review. The policy remains a clinical, laboratory, compliance and legal responsibility. Engineering makes the approved policy explicit, traceable, and operational.
Assay Version Management Requires More Than a Genetic Test Name
A test name is valuable for human communication. It is a poor control object.
“Comprehensive Cardiomyopathy Panel” does not identify the active assay version, genes, transcript policy, variant classes, reportable range, accepted specimen types, consent rules, payer dependencies, pipeline configuration, report template, or transition policy after an assay update.
The useful catalog object is a versioned clinical service definition. It needs a stable identifier, status, effective period, approved version, named owners, change history, and controlled links to dependent records.
The display name is one attribute. It is not the definition.
LOINC, CPT, ICD-10-CM, and Local Genetic Test Codes Must Resolve to One Service
Laboratories commonly maintain several identifiers for the same test:
- A local laboratory order code.
- A provider-facing orderable in an EHR or portal.
- A client-specific mapping.
- A LOINC code or mapping where appropriate.
- CPT mapping for procedure coding.
- ICD-10-CM guidance or payer dependencies.
- A reportable-result identifier.
LOINC supports standardized representation of laboratory observations and orders. ULOC is a common-orders subset, not a comprehensive catalog of laboratory-specific NGS panels. A large or laboratory-specific NGS panel may not have an exact matching LOINC order code. The laboratory should retain its local test code and approved service version, with a mapped LOINC code where an appropriate term exists. LOINC’s guidance on genetic testing and panels provides the relevant context; a LOINC mapping alone does not identify the laboratory’s complete assay scope or version.
For catalog exchange, HL7 v2 Master File Notification (MFN) messages with OM1 segments can communicate service/test master data between systems that support the agreed interface. HL7’s master-files specification describes this mechanism. MFN/OM1 exchange is distinct from placing a patient order and does not, by itself, establish a complete assay-version or clinical-policy model.
The NIH Genetic Testing Registry (GTR) provides submitted descriptions of genetic tests, methods, laboratory details, and ordering information. A GTR accession identifies a registry record, not the local order code or the laboratory’s approved assay version. It is a supporting reference, not the operational catalog or an NIH endorsement of the test.
Reduce ambiguity at the order boundary.
SmartReq supports structured requisition intake, required-field validation, consent-aware exceptions, and workflow decisions before incomplete or mismatched cases move downstream.
Assay Version Management: Release a Genetic Test Version Bundle
An assay change is rarely only an assay change. It may alter reportable content, limitations, documentation requirements, codes, pipeline settings, report language, or delivery rules.
The relevant control unit is a version bundle: the group of dependent records that must be reviewed together when a service changes.
| Version-controlled artifact | Why it belongs in the bundle |
|---|---|
| Clinical service definition | Establishes the orderable service and intended use |
| Assay definition | Establishes analytical method and scope |
| Gene, region, transcript, and variant-class scope | Defines evaluated and reportable content |
| Specimen and intake rules | Determines whether the laboratory may accept and process the case |
| Consent and documentation policy | Determines whether required documentation is present or requires review |
| Local code, LOINC, and client-order mappings | Determines how external systems identify the service |
| CPT and payer configuration | Determines commercial workflow interpretation |
| Pipeline and annotation configuration | Determines how analysis runs in production |
| Report specification | Defines methodology, limitations, structured results, and narrative output |
| Delivery rules | Determines how results reach EHRs, portals, and providers |
| Effective dates and transition policy | Determines which version governs an order, accession, report, amendment, or reanalysis |
A version bundle does not require a monolithic platform. It requires traceable relationships. A catalog may retain an approved assay identifier, a LIMS may retain workflow configuration, a pipeline platform may retain a release tag, a reporting system may retain a template version, and an interface engine may retain mapping revisions. The laboratory must be able to show that active components resolve to an approved service version.
Effective Dates and Genetic Test Version Transitions Need Defined Rules
Version boundaries create the most difficult cases:
- An order arrives before a new assay becomes effective but is accessioned after the release.
- A sample is accessioned before the release but analyzed after it.
- A failed case requires rework after a new version becomes active.
- A report is drafted using a previous template after a new assay is released.
- A historical case is amended or reanalyzed under current knowledge.
The laboratory should define whether the governing date is the order date, accession date, analytical-start date, final-report date, a manual release decision, or a controlled combination. The correct policy depends on laboratory-specific clinical and quality decisions. The system should make that decision visible and preserve it.
LIMS Test Catalog Management Needs a Connected Control Model
Each platform holds a valid but incomplete view of the service.
| System | Common strength | What it rarely governs alone |
|---|---|---|
| EHR | Provider-facing orderables and clinical context | Assay versions, laboratory specimen rules, pipeline releases, report eligibility |
| LIS | Order receipt, accessioning, results, laboratory operations | Full consent policy, external mappings, payer dependencies, bioinformatics release controls |
| LIMS | Sample tracking, wet-lab workflow, instruments, QC | Provider order experience, consent policy, billing, EHR result mapping |
| Bioinformatics platform | Analysis execution, annotation, QC, traceability | Order eligibility, documentation rules, payer policy, result delivery |
| Reporting system | Report assembly, templates, sign-out | Whether report content matches the ordered and performed service |
| Revenue-cycle system | Claims, coding, authorization, denials | Assay scope, report correctness, specimen acceptance |
| Spreadsheet or document repository | Reference information | Real-time validation, cross-system enforcement, release control |
The question is not which system should own every catalog field. The question is which system is the canonical source of the controlled clinical service definition, and how other systems receive, validate, or reconcile the information they need.
Clinical Laboratory Test Catalog Architecture: One Canonical Definition, Many Views
A practical target architecture has one canonical definition and several controlled system views:
- Provider portal and EHR orderable view
- SmartReq intake, documentation, and exception rules
- LIS and LIMS accessioning and specimen rules
- Intergenix HL7 v2 and FHIR order-mapping rules
- Bioinformatics workflow and pipeline-release rules
- Clinical review requirements
- ReportStudio report eligibility and template rules
- Billing, authorization, and payer mappings
- EHR result delivery and structured-result mappings
- Audit, approval, release, amendment, and historical records
The model needs to resolve the active service definition at order receipt, validate required conditions early, lock the applicable configuration at an approved workflow point, prevent report-template drift, and preserve historical context when a service evolves.
CMS guidance states that laboratory reports should be legible, understandable, and complete, and that systems should support accurate and reliable transmission of patient-specific data to the final report destination. CMS CLIA interpretive guidance addresses report content and result transmission.
Genetic Test Consent Workflow: Capture Is Not Validation
A scanned form, portal confirmation, or attached PDF is consent capture. Consent validation asks whether the documentation meets the active rule for the particular service and patient context.
Depending on laboratory policy and applicable requirements, that evaluation may consider form version, signatures, dates, patient identity, test linkage, provider attestation, jurisdictional requirements, clinical versus research distinction, secondary-finding preferences, and review exceptions.
Consent to undergo a genetic test and HIPAA privacy requirements answer different questions. Testing consent concerns whether the patient agreed to the test under applicable law and clinical policy. HIPAA governs the privacy and permitted use or disclosure of protected health information; it does not, by itself, establish informed consent to perform genetic testing.
HHS OCR guidance confirms that individually identifiable genetic information can be PHI when it meets the HIPAA definition. HHS also distinguishes privacy consent from HIPAA authorization. The catalog should therefore track testing-consent requirements separately from any applicable PHI-use or disclosure requirements. A HIPAA authorization is not a substitute for required testing consent, and testing consent does not replace any separate authorization required for a particular use or disclosure.
Connect external orders to laboratory rules and exception workflows.
Intergenix engineers validated HL7 v2 and FHIR order, status, and result workflows so laboratories can reconcile external clinical requests with controlled internal service definitions.
Genetic Test Catalog Governance Requires Named Owners
A data model does not create accountability. Catalog control requires a release model with named authority.
| Decision area | Accountable owner | Required contributors |
|---|---|---|
| Intended use, eligibility, reportability | Medical director or designated clinical leader | Genetic counseling, clinical operations, laboratory leadership |
| Assay scope, methodology, reportable range, limitations | Laboratory director | Molecular operations, bioinformatics, quality |
| Specimen and preanalytic requirements | Laboratory operations leader | Accessioning, quality, client services |
| Consent and documentation rules | Compliance and clinical leadership | Legal counsel, genetic counseling, laboratory operations |
| Orderables, LOINC, local codes, interface mappings | Laboratory informatics leader | Integration engineering, client implementation, operations |
| Pipeline release configuration | Bioinformatics leader | Laboratory director, quality, platform engineering |
| Report templates and sign-out rules | Medical director or reporting leader | Reporting operations, laboratory quality |
| CPT, payer, authorization, and order-to-cash mapping | Revenue-cycle leader | Client services, compliance, finance |
| Release approval and effective-date policy | Named change-control authority | All affected owners |
This model establishes who can approve a revised gene list, change a limitation statement, activate an EHR orderable, update consent requirements, alter a report template, or retire an older service version.
CMS guidance on verification of performance specifications states that laboratories must verify applicable performance characteristics before reporting patient results when an unmodified FDA-cleared or approved nonwaived test system is introduced under the specified circumstances. CMS verification guidance explains these requirements. Qualified laboratory leadership must determine the validation, verification, quality, and change-control obligations that apply to a specific test-system change.
Four Controls for a Defensible Genetic Test Catalog
A laboratory can assess genetic test catalog management before selecting new software.
1. Reconstruct the Clinical Service for Every Completed Case
For any completed patient case, can the laboratory identify the ordered service, active catalog version, applicable documentation rule, assay and pipeline configuration, report specification, delivery route, approvals and exceptions?
If the answer depends on staff memory, shared inboxes, or disconnected spreadsheets, the catalog is not a reliable clinical control system.
2. Confirm Genetic Test Order, Assay, and Report Consistency
Do the order, consent record, specimen rule, assay, pipeline, and report resolve to a compatible service version?
The control should detect mismatches before sign-out rather than after provider inquiry, patient complaint, billing exception, or report amendment.
3. Test the Assay Version Release Process
Can a laboratory publish a new service version through a defined process that identifies impacted records, validates changes, captures approvals, sets effective dates, and monitors post-release exceptions?
A release is incomplete when the new assay is live, but the EHR orderable, consent rule, pipeline, report template, payer mapping, or result interface still uses the prior definition.
4. Route Genetic Test Catalog Exceptions Early
Can the system identify and route orders that do not fit an active rule?
Examples include an older consent form, an invalid specimen type, an external code with no active mapping, a payer condition needing review, a mismatched report template, or a case requiring a transition-policy decision. A mature workflow detects these cases early, assigns ownership, and records resolution.
What NonStop Engineers Around the Catalog
A governed genetic test catalog platform provides a foundation for connecting approved service definitions with ordering, intake, analysis, reporting, and delivery.
NonStop builds and integrates the software, data model, workflow controls, and interfaces needed to make that platform work across the laboratory’s systems. Release procedures, named ownership, and an audit trail keep the service definition controlled as tests change.
- SmartReq supports structured requisition and intake workflows, including extraction, required-field validation, consent-aware exception handling, and routing of incomplete orders.
- Intergenix connects EHR, LIS, LIMS, portal, and downstream workflows through HL7 v2 and FHIR mappings, validation, reconciliation, and exception management.
- Custom LIMS and laboratory workflow engineering support accessioning, specimen tracking, wet-lab routing, QC gates, instrument workflow, and case-state controls tied to the approved service definition.
- Bioinformatics workflow engineering connects assay releases to production pipeline configuration, monitoring, re-run controls, and traceability.
- ReportStudio and clinical reporting engineering connect the performed service to approved report content, structured results, sign-out workflow, amendments and result delivery.
- Forward-deployed engineering gives laboratory teams an embedded technical partner to map the current state, establish the control model, integrate the required systems, and transfer durable ownership to the organization.
The result should not be another disconnected catalog interface.
It should be a traceable chain from orderable service to final clinical report.
Start Your Genetic Test Catalog Management Review With Three Complex Tests
Choose three tests:
- A high-volume panel that has changed gene content, methodology or reportable range.
- A test with complex consent, clinical history, or genetic counselling requirements.
- A service with multiple payer, EHR, client, or report-delivery pathways.
For each service, collect the provider-facing orderable, assay definition, consent rule, LOINC and local mappings, specimen requirements, pipeline configuration, report template, payer dependencies, delivery setup, and historical version policy.
Then ask one question:
Can every one of these records be tied to one approved, versioned clinical service definition?
If not, the laboratory has a catalog-control gap.
Assess the Controls Behind Your Genetic Test Catalog
NonStop’s Architecture Review maps whether test definitions, assay versions, consent rules, LOINC and local order mappings, laboratory workflow, pipeline releases, report templates, and result delivery are governed as one traceable clinical service.
Prefer a shorter initial conversation?
Book a 15-Minute Scoping CallGenetic Test Catalog Management FAQs
What is genetic test catalog management?
Genetic test catalog management is the governance of the clinical services a laboratory offers. It connects the test orderable, assay version, consent rules, specimen criteria, coding, workflow configuration, report logic, delivery requirements, and historical record for each service.
Why does a genetic test catalog need assay version control?
Assay version control records the analytical definition that applied to a case, including relevant methodology, gene content, reportable range, variant classes, limitations, and workflow configuration. Without it, a laboratory may not be able to reconstruct the service performed or determine whether a report describes the correct assay.
Does CLIA require consent for genetic testing?
CLIA does not generally require laboratories to document informed consent for requested tests. State requirements, institutional policies, provider responsibilities, test-specific considerations, and other applicable requirements may create consent obligations. Qualified clinical, laboratory, compliance, and legal stakeholders should determine the policy that applies. CDC guidance for molecular genetic testing discusses this distinction.
Is a LIMS enough for genetic test catalog management?
A LIMS can be central to test setup, sample tracking, wet-lab workflow, and quality-control operations. It may not govern provider-facing orderables, consent requirements, EHR mappings, payer dependencies, pipeline releases, report templates, and result-delivery rules. The essential requirement is a controlled and traceable definition that links relevant systems.

